A lot of people worry about self-injecting or about the side effects of GLP-1, like digestive issues
(A BMI of 30 is the marker for obesity and opens the door to coverage by insurance.) However, Nooms chief medical officer, Jeffrey Egler, MD, says the company uses more than BMI when determining if microdosing is right for a patient
Proper storage and handling will help maintain Lipo-Cs effectiveness throughout your treatment course
Lilly reported in ACHIEVE-1 that orforglipron lowered A1C by an average of 1.3% to 1.6% across doses, and the full results were published in The New England Journal of Medicine via PubMed in 2025
Consider working with a trainer or following a structured program designed for people in caloric deficit
Creating Your Custom Treatment Plan With your assessment, lab results, and goals in hand, your medical team will design your personalized treatment plan